September 15, 2021
Article
Immediate and second- and third-degree family members can benefit from colonoscopy screenings, new research results show.
Stereotactic ablative radiotherapy has similar overall and progression-free survival rates.
Among patients treated with the combination of nivolumab and ipilimumab, 23% were alive at 3 years, compared to 15% of patients treated with chemotherapy.
Cabozantinib (Cabometyx) was approved in 2016 for patients who have advanced renal cell carcinoma and who received prior anti-angiogenic therapy.
September 13, 2021
VOR33 aims to protect an individual’s healthy cells from anti-CD33 therapies and replace standard care transplants.
New research has found that the relative cardiovascular safety of different types of androgen deprivation therapy (ADT) for prostate cancer remains unresolved after the PRONOUNCE trial was terminated early.
The results of a 5-year follow-up study comparing trastuzumab (Ontruzant) and reference medicine trastuzumab show comparable cardiac safety profiles and long-term efficacy.
September 10, 2021
With CAR T-cell therapies showing promise for follicular lymphoma and marginal zone lymphoma, clinicians must weigh toxicity and tolerability almost as strongly as efficacy because patients can live years with these diseases
Video
Lola Fashoyin-Aje, MD, MPH, associate director of Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence, discusses the importance of promoting inclusion of members of racial and ethnic minority groups in cancer drug trials.
The European Association of Neuro-Oncology and the European Society for Medical Oncology published recommendations related to parenchymal brain metastases.
